Nandini Vijaisimha

Nandini Vijaisimha, with her deep-rooted expertise and passion, now stands as the Senior Director of India Corporate Affairs at MMS. In this pivotal role, she oversees and orchestrates the company’s corporate affairs strategies within the Indian context. Her activities encompass government and regulatory relations, corporate communications, and stakeholder engagement, ensuring that MMS’s values and objectives resonate in the region.

Her prior Director of Human Resources and Administration role has equipped her with a unique perspective, having managed cross-functional teams and strengthened HR processes. Nandini’s global interactions have allowed her to foster a cohesive alignment between teams scattered around the world, a skill she continues to leverage in her current role as she bridges MMS’s operations between India and its global counterparts.

Education and professional development have always been at the forefront of Nandini’s journey. She proudly holds a master’s diploma in Personnel Management and Industrial Relations from Bangalore University, India. Further amplifying her credentials, she also possesses an MBA in Human Resource Management from XLRI, Jamshedpur, India, and a bachelor’s degree in arts from Bangalore University. Her multiple HR certifications, coupled with international certification in executive coaching, serve as a testament to her unwavering commitment to ongoing education and professional excellence.

Beyond her academic and corporate achievements, Nandini boasts significant experience in coaching leaders, students, and professionals. Her expertise is particularly pronounced in the realm of Women Empowerment coaching, reflecting her dedicated approach to fostering growth and resilience in every individual she mentors.

Suggested For You

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

perspectives

August 20th, 2024

Clinical Study Protocols: A Comprehensive Guide to Best Practices From A Senior Medical Writer